Petroulia Stavroula, Hockemeyer Kathryn, Tiwari Shashank, Berico Pietro, Shamloo Sama, Banijamali Seyedeh Elnaz, Vega-Saenz de Miera Eleazar, Gong Yixiao, Thandapani Palaniraja, Wang Eric, Schulz Michael, Tsirigos Aristotelis, Osman Iman, Aifantis Ioannis, Imig Jochen
bioRxiv. 2024 Jul 24:2024.07.24.604899. doi: 10.1101/2024.07.24.604899.
Melanoma being one of the most common and deadliest skin cancers, has been rising since the past decade. Patients at advanced stages of the disease have very poor prognoses, as opposed to at the earlier stages. Nowadays the standard-of-care of advanced melanoma is resection followed by immune checkpoint inhibition based immunotherapy. However, a substantial proportion of patients either do not respond or develop resistances. This underscores a need for novel approaches and therapeutic targets as well as a better understanding of the mechanisms of melanoma pathogenesis. Long non-coding RNAs (lncRNAs) comprise a poorly characterized class of functional players and promising targets in promoting malignancy. Certain lncRNAs have been identified to play integral roles in melanoma progression and drug resistances, however systematic screens to uncover novel functional lncRNAs are scarce. Here, we profile differentially expressed lncRNAs in patient derived short-term metastatic cultures and BRAF-MEK-inhibition resistant cells. We conduct a focused growth-related CRISPR-inhibition screen of overexpressed lncRNAs, validate and functionally characterize lncRNA hits with respect to cellular growth, invasive capacities and apoptosis in vitro as well as the transcriptomic impact of our lead candidate the novel lncRNA XLOC_030781. In sum, we extend the current knowledge of ncRNAs and their potential relevance on melanoma.
Previously considered as transcriptional noise, lncRNAs have emerged as novel players in regulating many cellular aspects in health and disease including melanoma. However, the number and as well as the extent of functional significance of most lncRNAs remains elusive. We provide a comprehensive strategy to identify functionally relevant lncRNAs in melanoma by combining expression profiling with CRISPR-inhibition growths screens lowering the experimental effort. We also provide a larger resource of differentially expressed lncRNAs with potential implications in melanoma growth and invasion. Our results broaden the characterized of lncRNAs as potential targets for future therapeutic applications.
黑色素瘤是最常见且最致命的皮肤癌之一,在过去十年中发病率一直在上升。与疾病早期阶段相反,处于晚期的患者预后非常差。如今,晚期黑色素瘤的标准治疗方法是切除,然后进行基于免疫检查点抑制的免疫治疗。然而,相当一部分患者要么没有反应,要么产生耐药性。这凸显了对新方法和治疗靶点的需求,以及对黑色素瘤发病机制的更好理解。长链非编码RNA(lncRNA)是一类功能特征尚不明确的功能性分子,也是促进恶性肿瘤发生的有前景的靶点。某些lncRNA已被确定在黑色素瘤进展和耐药性中发挥不可或缺的作用,然而,用于发现新的功能性lncRNA的系统性筛选却很少。在这里,我们分析了患者来源的短期转移培养物和BRAF-MEK抑制耐药细胞中差异表达的lncRNA。我们对过表达的lncRNA进行了聚焦于生长相关的CRISPR抑制筛选,在体外验证并从细胞生长、侵袭能力和凋亡方面对lncRNA命中靶点进行功能表征,以及我们的主要候选新lncRNA XLOC_030781的转录组影响。总之,我们扩展了当前关于非编码RNA及其与黑色素瘤潜在相关性的知识。
lncRNA以前被认为是转录噪音,现在已成为调节包括黑色素瘤在内的健康和疾病中许多细胞方面的新分子。然而,大多数lncRNA的数量及其功能意义的程度仍然难以捉摸。我们提供了一种综合策略,通过将表达谱分析与CRISPR抑制生长筛选相结合来识别黑色素瘤中功能相关的lncRNA降低实验工作量。我们还提供了更多差异表达的lncRNA资源,它们可能对黑色素瘤的生长和侵袭有影响。我们的结果拓宽了lncRNA作为未来治疗应用潜在靶点的特征。